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SUMMARY 
 
The discoidin domain receptors, DDR1 and DDR2, are constitutively dimeric receptor 
tyrosine kinases that are activated by triple-helical collagen. Aberrant DDR signalling 
contributes to several human pathologies including many cancers. We have generated 
monoclonal antibodies (mAbs) that inhibit DDR1 signalling without interfering with collagen 
binding. The crystal structure of the monomeric DDR1 extracellular region bound to the Fab 
fragment of mAb 3E3 reveals that the collagen-binding discoidin (DS) domain is tightly 
associated with the following DS-like domain, which contains the epitopes of all mAbs. A 
conserved surface patch in the DS domain outside the collagen binding site is shown to be 
required for signalling. Thus, the active conformation of the DDR1 dimer involves collagen-
induced contacts between the DS domains, in addition to the previously identified association 
of transmembrane helices. The mAbs likely inhibit signalling by sterically blocking the 
extracellular association of DDR1 subunits. 
 
 
HIGHLIGHTS 
 
New monoclonal antibodies inhibit DDR1 signalling without blocking collagen binding. 
The DDR1 extracellular region consists of a DS and a DS-like domain. 
The collagen-binding DS domain contains a patch that is essential for signalling. 
The mAbs bind to the DS-like domain, preventing formation of the active DDR dimer. 
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INTRODUCTION 
 
Receptor tyrosine kinases (RTKs) control many fundamental cellular processes, such as cell 
proliferation, differentiation, migration and metabolism (Lemmon and Schlessinger, 2010). 
RTK activity is normally tightly controlled and dysregulation of RTK activity is associated 
with many human cancers and other pathologies. Ligand binding to the extracellular region 
of RTKs leads to autophosphorylation of their cytoplasmic kinase domains, creating docking 
sites for effectors of downstream signalling. The two major strategies for controlling 
unwanted RTK activity in human patients are inhibition by monoclonal antibodies (mAbs) 
directed against their extracellular regions or by small molecules targeting the kinase active 
site (Adams and Weiner, 2005; Gschwind et al., 2004). 
  The discoidin domain receptors, DDR1 and DDR2, are RTKs that are activated by 
several types of triple-helical collagen, a major component of the animal extracellular matrix 
(Leitinger, 2011; Shrivastava et al., 1997; Vogel et al., 1997). The DDRs are widely 
expressed in mammalian tissues and have important roles in embryo development and human 
disease (Vogel et al., 2006). For example, DDR1 is essential for mammary gland 
development (Vogel et al., 2001) and DDR2 for the growth of long bones (Labrador et al., 
2001). DDR2 mutations in humans cause a rare, severe form of dwarfism (Ali et al., 2010; 
Bargal et al., 2009). The DDRs are also implicated in cancer, fibrotic diseases, 
atherosclerosis and arthritis (Vogel et al., 2006). Mechanistically, the DDRs have several 
features that distinguish them from other RTKs. Compared with the rapid response of typical 
RTKs to their soluble ligands (e.g. growth factors), collagen-induced DDR 
autophosphorylation is slow and sustained (Shrivastava et al., 1997; Vogel et al., 1997). 
Furthermore, Src kinase plays an essential role in DDR activation (Ikeda et al., 2002). 
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  Both DDRs are composed of an N-terminal discoidin (DS) domain (Baumgartner et 
al., 1998), followed by a predicted DS-like domain (our unpublished results; Lemmon and 
Schlessinger, 2010), an extracellular juxtamembrane (JM) region, a transmembrane (TM) 
helix, a large cytosolic JM region, and a C-terminal tyrosine kinase domain. Collagen binds 
to the DS domain and the structural determinants of the DDR-collagen interaction have been 
extensively studied (Carafoli et al., 2009; Ichikawa et al., 2007; Konitsiotis et al., 2008; 
Leitinger, 2003; Xu et al., 2011). The remainder of the extracellular region has not been 
characterised structurally or functionally. 
  How collagen binding results in DDR activation is a major unresolved question. 
DDR1 can be activated by short collagen-like peptides, showing that DDR clustering by 
multivalent collagen assemblies (e.g. fibrils) is not essential for activation (Konitsiotis et al., 
2008). The DDRs are constitutive dimers at the cell surface and residues within the TM helix 
are required for signalling (Noordeen et al., 2006). In fact, a comprehensive analysis has 
shown that the DDRs have the highest propensity of TM helix self-interactions in the entire 
RTK superfamily (Finger et al., 2009). Therefore, the conformational changes resulting from 
collagen binding are likely to occur in the context of a stable DDR dimer. Our crystal 
structure of a DDR2 DS-collagen peptide complex (Carafoli et al., 2009) revealed a 1:1 
complex and did not clarify how collagen binding affects the conformation of the DDR 
dimer. Here, we report the functional characterisation of a set of novel inhibitory anti-DDR1 
mAbs and the crystallisation of the almost complete extracellular region of DDR1 bound to a 
mAb Fab fragment. The crystal structure led to the discovery of DDR1 residues that are 
required for signalling even though they are not part of the known collagen binding site. 
These results provide new insight into the process of DDR1 activation. 
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RESULTS 
 
Generation and Characterisation of anti-DDR1 mAbs 
We immunised mice with a recombinant protein spanning the entire extracellular region of 
human DDR1 and obtained seven anti-DDR1 mAbs. All seven mAbs were found to inhibit 
the collagen-induced autophosphorylation of DDR1 expressed in HEK293 cells (Figure 1) 
and this inhibitory activity was retained by Fab fragments generated from five of the seven 
mAbs (Figure S1). Dose-dependent inhibition experiments revealed no substantial 
differences in activity between the mAbs, which all reduced DDR1 phosphorylation to 
background levels when applied at 2 μg/ml, but were only partially active inhibitory at 
0.2 μg/ml (data not shown). Similarly, an enzyme-linked immunosorbent assay (ELISA) with 
the immobilised DDR1 extracellular region (His-DDR1) showed that all mAbs bound with 
comparable apparent dissociation constants of ~2 nM (data not shown). In an ELISA with 
domain deletion constructs, all seven mAbs bound to the membrane-proximal DS-like 
domain (His-ΔDS-DDR1), but not to the membrane-distal DS domain containing the 
collagen binding site (His-DS-DDR1) (Figure 2A). This result suggested that the inhibitory 
activity of the mAbs on cells was unlikely to be the result of a block of collagen binding. 
Indeed, when we tested a subset of mAbs in a direct collagen binding assay, we found that 
binding of DDR1-Fc to a high-affinity collagen peptide (III-23, (Xu et al., 2011)) was not 
affected by the addition of mAbs (Figure 2B). The combined results demonstrate that the 
novel anti-DDR1 mAbs inhibit DDR1 function by interfering with the signal transduction 
process resulting from collagen binding. 
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Crystal Structure of a DDR1-Fab Complex 
For several years, we had attempted unsuccessfully to obtain diffracting crystals of the 
extracellular regions of DDR1 or DDR2. Fab fragments of mAbs have been instrumental in 
facilitating the crystallisation of many recalcitrant proteins (Nettleship et al., 2008). We 
therefore screened the Fab fragments of six anti-DDR1 mAbs for complex formation and co-
crystallisation with the extracellular region of DDR1 (the 1F7 Fab could not be used because 
it aggregated in solution). Because the His-DDR1 construct used for mAb generation 
included the JM region that is predicted to be unstructured, we produced a new construct 
terminating at the predicted C-terminus of the DS-like domain, Asp367. All Fab fragments 
bound to this shortened DDR1 construct, as determined by analytical size exclusion 
chromatography (data not shown). We obtained crystals of the DDR1-3E3 Fab complex and 
determined its structure at a resolution of 2.8 Å (Table 1). 
  The extracellular region of DDR1 revealed by the crystal structure is a compact 
structure measuring approximately 70 Å x 50 Å x 40 Å (Figure 3A). The DS and DS-like 
domains are arranged such that the long axes of their β-barrels are roughly perpendicular to 
each other. There is an extensive interface between the two domains that buries 1410 Å2 of 
solvent-accessible surface (i.e. the interface measures ~700 Å2). The domain arrangement in 
DDR1 is reminiscent of the tandem DS domains in neuropilins (Appleton et al., 2007; 
Vander Kooi et al., 2007), but the second domain is rotated differently in the two proteins 
(Figure S2). The N- and C-termini of the crystallised DDR1 construct are located on the 
same face of the molecule near the interdomain linker. In the intact receptor, the C-terminus 
of the crystallised construct would be linked to the TM helix by the 50-residue JM region. 
The DDR1 DS domain is very similar to the DDR2 DS domain (r.m.s. deviation of 0.61 Å 
for 156 Cα atoms), which was previously crystallised in complex with a collagen-like peptide 
(Carafoli et al., 2009). The collagen binding loops of the DDR1 DS domain, which are 
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opposite the DS-like domain, have weak electron density and high temperature factors, 
suggesting that they are quite mobile in the absence of the collagen ligand. The 3E3 Fab 
fragment is bound near the C-terminus of the DS-like domain, distant from the collagen 
binding site (for a description of the epitope, see below). 
 
Structure of the DS-like Domain 
As predicted (our unpublished results; Lemmon and Schlessinger, 2010), the DS-like domain 
belongs to the coagulation factor V/VIII type C superfamily. A search with the program SSM 
(Krissinel and Henrick, 2004) showed that the DS-like domain of DDR1 is most closely 
related to family 32 carbohydrate binding modules (CBMs) (Boraston et al., 2004), but a 
pairwise alignment of the DS and DS-like domains of DDR1 gave only a marginally lower 
Z-score and a r.m.s. deviation of 3.0 Å for 120 aligned Cα atoms (Figure 3B). To facilitate 
the comparison of the DS and DS-like domains, the eight β-strands that are common to both 
domains have been labelled β1-β8. The DS-like domain contains five additional strands, 
labelled βa-βe, in a long insertion between β1 and β2. Both domains are characterised by two 
antiparallel β-sheets with jellyroll topology (β1-β2-β7-β4 sheet and β5-β6-β3-β8 sheet). At 
one end of the β-barrel (the “bottom”) the β2-β3 and β6-β7 loops cross over between the 
sheets and create a relatively flat surface. At the other end (the “top”), several long and 
irregular loops protrude from the barrel. In the DS domain, these loops constitute the collagen 
binding site (Carafoli et al., 2009; Ichikawa et al., 2007; Leitinger, 2003). In the DS-like 
domain, they contribute the extra strands βa-βe, two N-linked glycosylation sites (Asn211 
and Asn260) and a calcium binding site. The calcium ion is coordinated by the side chains of 
Asp233 and Glu361, as well as by three main chain carbonyl groups; an analogous calcium 
coordination is seen in many family 32 CBMs (Boraston et al., 2004). It is noteworthy that 
the glycosylation site at Asn211 and the calcium ligands are strictly conserved in all 
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vertebrate DDRs (Figure S3). A second ion in the DS-like domain was also modelled as 
calcium, but this ion appears to be bound more weakly and may be a crystal artefact (not 
shown). The DS-like domain of DDR1 contains three cysteines: Cys303 and Cys348, which 
form a deeply buried disulphide bridge linking the adjacent β4 and β7 strands, and Cys287, 
which is unpaired and also buried. A previous study suggested that Cys303 and Cys348 may 
be involved in the covalent dimerisation of DDR1 (Abdulhussein et al., 2008). However, the 
DS-like domain would have to unfold for these two residues to become available for 
intermolecular disulphide bridges. The disulphide-linked dimers seen in cell lysates in that 
study therefore are more likely to have resulted from oxidation following denaturation. 
  The interface between the DS and DS-like domains of DDR1 is formed between the 
bottom of the DS domain, in particular the β4-β5 and β6-β7 loops, and the long convoluted 
insertion between strands β1 and β2 of the DS-like domain (Figure 3C). A key interface 
residue is Trp187, which is located in the short linker between the two domains and which 
interacts with residues of both the DS domain (Leu94 and Val160) and the DS-like domain 
(Leu191, Leu192, Leu228, Ala232). With the exception of Leu192 and Ala232, these 
residues are strictly conserved in all vertebrate DDRs (Figure S3). Also conserved is an ion 
pair spanning the interface, involving Arg124 of the DS domain and Asp216 of the DS-like 
domain. Additional interdomain contacts are made between the 134-138 and 245-253 loops 
(Figure 3C). Even though the shape complementarity of the domain interface is not 
particularly high (sc-value of 0.56; Lawrence and Colman, 1993), its size and the 
conservation of key interface residues suggest that the domain arrangement seen in our 
structure is stable and representative of DDRs in general. 
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DS Domain Residues Required for DDR1 Signalling 
The DDRs are believed to be constitutive dimers at the cell surface (Mihai et al., 2009; 
Noordeen et al., 2006). Analytical ultracentrifugation of the crystallised DDR1 ectodomain 
construct shows it to be monomeric at concentrations of up to 6.8 mg/ml (data not shown), in 
agreement with an earlier result obtained by size exclusion chromatography for His-DDR1 
(Leitinger, 2003). However, because the high protein concentration in the crystal might 
favour a very weak dimer association, we inspected the crystal lattice for DDR1 dimers. 
There was only one plausible dimer. The interface between the two DDR1 molecules in this 
dimeric lattice contact is dominated by two identical, symmetry-related, contacts and buries 
1580 Å2 of solvent-accessible surface with good shape complementarity (sc-value of 0.64). In 
each of the symmetry-related contacts, four DS domain residues, Arg32, Leu99, Leu152 and 
Tyr183, interact with Leu247 and Arg248 of of the other DDR1 molecule (Figure 4A). The 
four DS domain residues in the contact are strictly conserved in DDR1 and DDR2 from 
several species, whereas Leu247 and Arg248 are variable (Figure S3). To test whether these 
DDR1 regions are required for function, we expressed three DDR1 mutants (R32E, L152E 
and L247E/R248E) in HEK293 cells and measured their collagen-induced 
autophosphorylation. Flow cytometry showed that the mutants were expressed at the cell 
surface similarly to wild-type DDR1 (Figure 4B). Furthermore, SDS-PAGE analysis of the 
mutants showed the characteristic two bands corresponding to the immature (intracellular) 
and mature (cell surface-expressed) glycoforms of the receptor (Noordeen et al., 2006) 
(Figure 4C). The L247E/R248E double mutation had no effect on DDR1 activation 
(Figure 4C), indicating that the dimeric crystal lattice contact does not recapitulate a 
signalling state of the receptor. In sharp contrast, the R32E and L152E mutations abrogated 
DDR1 activation (Figure 4C). This result was unlikely to be due to an effect on ligand 
binding, given that the two mutations are distant from the high-affinity collagen binding site 
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(Carafoli et al., 2009). Indeed, collagen binding experiments with soluble DDR1 R32E and 
DDR2 L152E proteins (Figure 4D and data not shown) confirmed that these mutants are not 
defective in collagen binding. These findings demonstrate that the conserved surface patch in 
the DS domain containing Arg32 and Leu152 is required for DDR1 signalling, even though it 
is not part of the primary collagen binding site. 
 
Epitopes of Anti-DDR1 mAbs 
The 3E3 epitope is formed from three regions of the DDR1 DS-like domain, which are 
discontinuous in sequence, but contiguous in space: the start of β3 (Ala279, Gln281, Ala282), 
the β6-β7 loop (Ser 335, Pro337, Gly340, Arg341, Val342) and the very end of the DS-like 
domain (Ile365, Asp367) (Figure 5). The 3E3 Fab uses predominantly aromatic residues to 
recognise this epitope: Thr30, Phe32, Tyr34, Tyr49 and Leu50 of the light chain; and Ile31, 
Trp33, Tyr52, Tyr56 and Tyr96 of the heavy chain. In total, the DDR1-3E3 interface buries 
1390 Å2 of solvent-accessible surface and has a high shape complementarity value of 0.68, a 
typical value for antibody-antigen complexes (Lawrence and Colman, 1993). The finding that 
mAb 3E3 binds close to the C-terminus of the DS-like domain suggests that it may inhibit 
DDR1 function by preventing the association of the DS-like domains and/or JM regions in 
the signalling DDR1 dimer. The JM region is unlikely to make a major contribution to 3E3 
binding, however, given that the 3E3 Fab and the truncated DDR1 ectodomain construct used 
for crystallisation form a stable complex upon size exclusion chromatography (see 
Experimental Procedures). 
  To better understand how the anti-DDR1 mAbs inhibit DDR1 function, it was of 
interest to determine the epitopes of the other mAbs as well. We therefore made a series of 
DDR1 mutants, which targeted all linear and non-conservative human-to-mouse substitutions 
in the DS-like domain (Figure S3). These DDR1 mutants were expressed in HEK293 cells 
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and mAb binding was measured by flow cytometry (Figure 6A, Figure S4). Mutant mut7 
(R341H/A343G) was consistently expressed at lower levels than the wild-type protein, 
suggesting that the mutation may have compromised the DDR1 structure. All other mutants 
were expressed at similar levels to the wild-type protein. Saturating concentrations of all but 
one mAbs gave similar fluorescence profiles for wild-type DDR1. The single exception was 
1F10, which is a different isotype (IgG2b) than the other anti-DDR1 mAbs (IgG1) and 
therefore may be detected less well by the secondary Ab. 
  Four of the DDR1 mutants (mut2, mut3, mut4, mut7) showed unperturbed binding of 
all seven mAbs. The mut1 mutation (203-YLSEAVY to QLSEVMVH) abolished binding of 
mAbs 3G10, 3H10 and 7A9. The mut6 mutation (M318V/N321A/N325S) abolished binding 
of mAbs 1F7 and 1F10. The mut5 mutation (A279T/A282T) reduced binding of mAb 3E3 by 
~70% (mean fluorescence data in Figure S4). Inspection of the DDR1-3E3 interface 
structure (Figure 5) suggests that, in order to completely disrupt 3E3 binding, Arg341 would 
have to be substituted in addition to Ala279 and Ala282. Given that Arg341 (mut7) interacts 
with Met318 (mut6), disruption of 3E3 binding is likely to require a combination of mut5-7, 
i.e. a complete reconfiguring to the mouse structure at the base of the DS-like domain. 
Binding of mAb 5D5 was not affected by any of the mutations and we assume that the 5D5 
epitope similarly is a combination of the linear sequence motifs targeted in our experiments. 
In summary, the six inhibitory anti-DDR1 mAbs for which the epitopes could be defined 
(either by mutation or by structure determination) bind to two distinct regions of the DS-like 
domain that are >50 Å away from the collagen binding site in the DS domain (Figure 6B). 
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DISCUSSION 
 
In this paper we report three major findings that advance the mechanistic understanding of 
DDR signalling: First, crystal structure analysis has revealed that the extracellular region of 
DDRs consists of two structurally related domains, a collagen-binding DS domain and a 
DS-like domain. Second, we have generated anti-DDR1 mAbs that inhibit collagen-induced 
DDR1 activation by binding to the DS-like domain. Third, we have identified a conserved 
surface patch in the DS domain that is distinct from the collagen binding site, yet required for 
DDR activation. These results are integrated into a working model of how collagen binding 
might alter the extracellular structure of DDRs and thereby lead to receptor activation. 
  The N-terminal domain of DDRs has long been recognised as a member of the DS 
superfamily (e.g. Johnson et al., 1993; Karn et al., 1993) and its role in collagen binding is 
understood in atomic detail (Carafoli et al., 2009; Ichikawa et al., 2007). Our new crystal 
structure shows that the second DDR domain is a distant relative of the DS domain, termed 
the DS-like domain. Tandem repeats of DS domains occur in a number of secreted and cell 
surface proteins (Baumgartner et al., 1998; Kiedzierska et al., 2007). In the blood coagulation 
factors V and VIII, the two DS domains are arranged side-by-side with limited contacts 
between them, so that their top loops can both interact with the same cell membrane (Adams 
et al., 2004; Ngo et al., 2008; Shen et al., 2008). In neuropilin-1 and -2, the two DS domains 
are related by a ~90° rotation and form a compact structure, as in DDR1 (Appleton et al., 
2007; Vander Kooi et al., 2007). This angled arrangement in DDR1 results in the C-terminus 
of the DS-like domain emerging near the interdomain linker. The presumably unstructured 
JM region of DDR1 linking the DS-like domain to the TM helix (residues 368-417) contains 
12 prolines and a number of predicted N- and O-linked glycosylation sites. If fully extended, 
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it would project the DS and DS-like domains of DDR1 ~150 Å from the cell surface. The JM 
regions of other DDRs are similarly long, ranging from 32 to 74 residues. 
  mAbs directed against RTKs are invaluable tools for research and have been 
developed into successful therapeutics (Adams and Weiner, 2005). We have characterised 
seven anti-DDR1 mAbs that inhibit DDR1 function by binding to two distinct regions in the 
DS-like domain. Notably, Fab fragments derived from these mAbs were equally effective as 
DDR1 inhibitors. No mAbs were obtained that bind to the DS domain, possibly reflecting the 
higher degree of surface conservation in that domain (not shown). In agreement with their 
epitope locations, the mAbs inhibit DDR1 function without blocking collagen binding. We 
think that they do so by preventing the proximity of the two DS-like domains and the 
following JM regions in the collagen-bound, signalling, state of the DDR1 dimer (Noordeen 
et al., 2006). Deletion of the DS-like domain or JM region of DDR1 results in receptors that 
are not trafficked to the cell membrane, so the contribution of these regions to signalling 
could not be studied (Noordeen et al., 2006). Remarkably, however, the DS-like domain of 
DDR2 could be deleted without abrogating collagen-induced receptor autophosphorylation 
(Leitinger, 2003), suggesting that the DS-like domain is not making any essential contacts in 
the signalling DDR dimer. This leaves the collagen-bound DS domain as the most likely site 
of contact between the extracellular regions of the two DDR protomers in the signalling 
dimer. 
  An analysis of crystal lattice contacts in the DDR1-3E3 Fab structure led to the 
fortuitous discovery of functionally important residues near the base of the DS domain, close 
to the interface with the DS-like domain and distant from the collagen binding site at the top 
of the DS domain. The patch formed by these residues is the largest concentration of 
conserved surface residues in the extracellular region of DDRs apart from the collagen 
binding site, consistent with its essential role in signalling. We think that the conserved patch 
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is involved in mediating protomer contacts in the signalling DDR dimer, either by forming a 
direct DS-DS interface or by providing a secondary collagen binding site. The latter 
alternative is more appealing, as it provides a plausible mechanism whereby collagen could 
cross-link two DS domains (analogous to the “composite binding site” model discussed by 
Carafoli et al., 2009). In solution, the isolated DDR2 DS domain binds a 28-residue collagen 
peptide with 1:1 stoichiometry (Carafoli et al., 2009). However, inspection of the crystal 
lattice of this DS-collagen complex reveals that the conserved patch is involved in a lattice 
contact with the N-terminal glycine-proline-hydroxyproline triplets of the collagen peptide. 
This intriguing observation may suggest that the conserved patch in the DS domain indeed 
has weak affinity for collagenous sequences and, therefore, could provide a secondary 
collagen binding site in dimeric, full-length, DDR. 
 Whichever interactions are formed between the DS domains and the collagen ligand, 
they are expected to lead to structural changes within the DDR dimer that are propagated 
across the cell membrane to result in DDR autophosphorylation (Noordeen et al., 2006). 
Tight coupling of the extracellular conformational changes to intracellular domain 
arrangements is difficult to imagine in the DDRs, given their long, and presumably flexible, 
JM regions. Recent studies of the epidermal growth factor receptor (EGFR) have shown that 
the conformational coupling across the cell membrane is looser than commonly believed 
even in a receptor with less extensive JM regions (Lu et al., 2010; Mi et al., 2011). However, 
one important difference is that the TM helices of DDRs have a much higher propensity for 
self-interactions than that of EGFR (Finger et al., 2009). We propose that the TM helices are 
largely responsible for constitutive DDR dimerisation (Noordeen et al., 2006), but that 
collagen-induced interactions involving the DS domains are additionally required for DDR 
activation. 
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EXPERIMENTAL PROCEDURES 
 
DNA Constructs and Site-Directed Mutagenesis 
All mutations were generated by strand overlap extension PCR using a cDNA of human 
DDR1 as a template (Leitinger, 2003). The PCR primers used to generate these constructs are 
available on request. The amplified DNAs were cloned into the mammalian expression 
vectors pcDNA3.1/Zeo (Invitrogen) or pRK5 (BD Pharmingen) for expression of full-length 
proteins, or into modified pCEP vectors (Kohfeldt et al., 1997) for expression of soluble 
proteins. All PCR-derived DNA constructs were verified by sequencing. 
 
Production of Soluble DDR1 Proteins 
The following proteins were produced as described (Leitinger, 2003): His-DDR1 contains the 
entire extracellular region of human DDR1 (residues 19-416 of UniProt entry Q08345). His-
DDR2 contains the entire extracellular region of human DDR2 (residues 22-398 of UniProt 
entry Q16832). His-DS-DDR1 and His-ΔDS-DDR1 are deletion constructs based on His-
DDR1. His-DS-DDR1 lacks the DS-like domain (Δ201-369) and His-ΔDS-DDR1 lacks the 
DS domain (Δ31-185); both proteins retain the JM region. DDR1-Fc contains the entire 
DDR1 extracellular region fused to a C-terminal human IgG1 Fc sequence (Leitinger, 2003; 
Xu et al., 2011). 
  The DDR1 construct for crystallography contains the DS and DS-like domains of 
human DDR1 (residues 30-367) fused to a C-terminal His-tag (AAAHHHHHH). A vector-
derived APLA sequence is present at the N-terminus of the mature protein. The protein was 
produced in human embryonic kidney HEK293 c18 cells (ATCC). The cells were grown at 
37° C with 5% CO2 in Dulbecco’s modified Eagle’s medium/F12 (Invitrogen) containing 
10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin, 100 μg/ml streptomycin and 
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250 μg/ml geneticin. The cells were transfected with the pCEP-Pu expression plasmid using 
Fugene (Roche Diagnostics) and selected with 1 μg/ml puromycin (Sigma). Confluent cells 
in a HYPERFlask (Corning) were washed twice with PBS and incubated with serum-free 
medium for 3-4 weeks, with weekly medium exchanges. The pooled serum-free conditioned 
medium was loaded onto a 5-ml HisTrap column (GE Healthcare) using an Äkta Purifier (GE 
Healthcare). The protein was eluted with 500 mM imidazole in PBS, concentrated using a 
Vivaspin centrifugal device (Sartorius), and further purified on a Superdex 200 HR10/30 size 
exclusion chromatography column (GE Healthcare) with Tris-buffered saline (TBS) (25 mM 
Tris, 150 mM NaCl, 2 mM KCl, pH 7.4) as the running buffer. 
 
Generation of anti-DDR1 Antibodies 
To prepare an untagged antigen for immunisation, 500 μg of His-DDR1 (Leitinger, 2003) 
were digested with 25 U EKMax enterokinase (Invitrogen) for 16 h at 4° C. EKMax was 
removed with EK-Away resin (Invitrogen) according to the manufacturer’s protocol. 
Uncleaved His-DDR1 and the cleaved tag were removed with TALON metal affinity beads 
(Clontech). The untagged DDR1 protein was dialysed against PBS and concentrated to 
2 mg/ml by ultrafiltration. Mouse anti-DDR1 monoclonal antibodies (mAbs) were generated 
by immunising female BALB/c mice with the untagged DDR1 protein. Three days after the 
final boost one mouse was sacrificed to obtain splenocytes for hybridoma production by 
standard procedures. Hybridoma cell supernatants were screened against DDR1-Fc and His-
DDR1 proteins by enzyme-linked immunosorbent assay (ELISA). Reactive hybridoma 
supernatants were further screened for recognition of native DDR1 by cell-based ELISA, 
using HEK293 cells expressing full-length DDR1. Positive hybridoma cells were subcloned 
by limited dilution and screened as above. The isotype of each mAb was determined by 
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standard methods. All mAbs are of the IgG1 isotype, with the exception of mAb 1F10, which 
is IgG2b. 
 
Antibody and Fab Fragment Production 
Hybridoma cells were grown at 37° C with 5% CO2 in RPMI-1640 medium (Invitrogen) 
containing 10% fetal bovine serum, 1 mM sodium pyruvate, 10 U/ml penicillin, 100 μg/ml 
streptomycin and 1μg/ml fungizone (Invitrogen). The serum concentration was gradually 
reduced to 5% in a final culture volume of 1 litre. The hybridoma cell culture supernatant was 
loaded onto a 2 x 1-ml HiTrap rProtein A column (GE Healthcare). The mAbs were eluted 
with Immunopure gentle elution buffer (Pierce) and dialysed against TBS. Fab fragments 
were generated with a Fab Preparation Kit (Pierce) according to the manufacturer’s protocol. 
Briefly, 8 mg of mAb were incubated overnight at 37° C with activated papain immobilised 
on agarose resin. The Fc fragment and undigested mAb were removed using a 1-ml HiTrap 
rProtein A column (GE Healthcare), yielding ~3 mg of Fab fragment. The Fab fragments 
used in co-crystallisation experiments were further purified by size exclusion 
chromatography on a Superdex 200 HR10/30 column (GE Healthcare) with TBS as the 
running buffer. 
 
mAb cDNA Synthesis and Sequencing 
Total RNA was prepared from ~107 3E3 hybridoma cells using the RNeasy Mini Kit 
(Qiagen). The RNA was reverse-transcribed and cDNA fragments encoding the heavy- and 
light-chain variable regions of the mAb were amplified using the SuperScript III One-Step 
RT-PCR system (Invitrogen) and suitable universal primers (Orlandi et al., 1989). The PCR 
products were gel-purified and sequenced using the same primers. The mAb residues are 
numbered according to Al-Lazikani et al. (1997). 
 18 
 
DDR1 Activation Assay 
The assay was performed as described (Leitinger, 2003). Briefly, HEK293 cells were grown 
in 12-well tissue culture plates and transfected with 2 μg/well of DDR1 wild-type or mutant 
plasmid DNA using calcium phosphate precipitation. 24 h after transfection the cells were 
incubated with serum-free medium for 16 h. Cells were then stimulated with 10-50 μg/ml 
acid-soluble rat tail collagen I (Sigma) for 90 min at 37° C before being lysed. In the 
inhibition experiments, anti-DDR1 mAbs or their Fab fragments were added together with 
collagen I, without prior incubation. Aliquots of the cell lysates were subjected to SDS-
PAGE and blotted onto nitrocellulose membranes. The blots were first probed with a mouse 
anti-phosphotyrosine mAb (clone 4G10, Upstate Biotechnology) followed by a horseradish 
peroxidase-conjugated sheep anti-mouse Ig (Amersham Biosciences). Detection was done by 
Enhanced Chemiluminescence Plus (Amersham Biosciences) using an Ettan DIGE Imager 
(GE Healthcare). To reprobe the blots, the membranes were treated with Ab stripping 
solution (Alpha Diagnostic International), followed by incubation with rabbit anti-DDR1 Ab 
(SC-532, Santa Cruz Biotechnology) and finally goat horseradish peroxidase-conjugated anti-
rabbit Ig (P0448, DAKO). 
 
ELISA and Solid Phase Binding Assays 
Recombinant DDR proteins, diluted to 10 μg/ml in 50 mM Tris, 100 mM NaCl, pH 8.5, were 
coated in 50 μl aliquots onto Maxisorp 96-well plates (Nalgene NUNC) overnight at room 
temperature. The wells were blocked with 150 μl of incubation buffer (PBS containing 40 
μg/ml bovine milk κ-casein (Sigma) and 0.05% Tween-20) for 1 h at room temperature. 
Anti-DDR1 mAbs were added at 30 μg/ml in 50 μl aliquots and incubated for 1.5 h at room 
temperature. The wells were washed 6 times with incubation buffer, followed by the addition 
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of horseradish peroxidase-conjugated sheep anti-mouse Ig (Amersham Biosciences, 1:1000 
dilution in incubation buffer) for 1.5 h at room temperature. After 6 washes as above, bound 
mAbs were detected with 75 μl/well of 500 μg/ml o-phenylenediamine dihydrochloride 
(Sigma-Aldrich) in 50 mM citrate-phosphate pH 5.0. The reaction was stopped after 3-5 
minutes with 50 µl/well of 3 M H2SO4. The absorbance at 492 nm was measured using a 
Sunrise 96-well plate reader (Tecan). 
  To measure DDR1 binding to the collagen-derived peptide III-23, Immulon 2 HB 
96-well plates (Fisher Scientific) were coated overnight at room temperature with 10 μg/ml 
III-23 in 10 mM acetic acid (Xu et al., 2011). The wells were then blocked in incubation 
buffer as described above. DDR1-Fc proteins were added in various concentrations and 
incubated for 3 h. In the inhibition experiments, the DDR1-Fc protein was incubated with 
anti-DDR1 mAbs for 30 minutes at room temperature before being added to the wells. After 
6 washes with incubation buffer, bound DDR1-Fc was detected with horseradish peroxidase-
conjugated goat anti-human Fc (Jackson ImmunoResearch Laboratories, 1:3333 dilution), 
added for 1 h at room temperature. The assay was completed as described above. 
 
Flow Cytometry 
HEK293 cells were grown in 6-well plates and transfected with 5 μg/well of DDR1 wild-type 
or mutant plasmid DNA using calcium phosphate precipitation. 48 h after transfection, the 
cells were dissociated with non-enzymatic cell dissociation solution (Sigma) and resuspended 
in PBS containing 1% BSA. The cells were incubated with primary mAb or mouse IgG1 
isotype control Ab (Cambridge Bioscience) at 10 μg/ml in 100 μl PBS/BSA for 30 minutes 
on ice, followed by three washes with PBS/BSA and incubation with FITC-conjugated goat 
anti-mouse IgG (F-9006, Sigma) for 30 min on ice. After three washes as above, the cells 
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were resuspended in 2% formaldehyde in PBS and analysed on a FACS Calibur flow 
cytometer using Cell Quest Pro software (Becton Dickinson Biosciences). 
 
Crystal Structure Determination 
The purified DDR1 protein for crystallography and the 3E3 Fab fragment were mixed in an 
equimolar ratio and incubated on ice for 30 minutes. The solution was subjected to size 
exclusion chromatography on a Superdex 200 HR10/30 column (GE Healthcare) with TBS as 
the running buffer. The DDR1-3E3 Fab complex eluted as a single peak and was 
concentrated to 6 mg/ml. Sitting drop vapour diffusion crystallisation screens were set up 
using a Mosquito nanolitre robot (TTP LabTech). Crystals were obtained after 1-2 days at 
room temperature using 2% Tacsimate pH 5.0 (Hampton Research), 100 mM sodium citrate 
tribasic dihydrate pH 5.6, 20% PEG 3350 as precipitant. Crystals were flash-frozen in liquid 
nitrogen after a brief soak in mother liquor supplemented with 25% glycerol. Diffraction data 
were collected at 100 K on station I02 at the Diamond Light Source (Oxfordshire, UK), The 
data were processed with MOSFLM (www.mrc-lmb.cam.ac.uk/harry/mosflm) and programs 
of the CCP4 suite (CCP4, 1994). The DDR1-3E3 Fab structure was solved by molecular 
replacement with PHASER (McCoy et al., 2007) using as search models the DDR2 DS 
domain (PDB entry 2wuh) and a Fab fragment of an Ab directed against neuropilin-2 (PDB 
entry 2qqk). The electron density map calculated from the correctly positioned search models 
showed weak density for several β-strands in the DS-like domain, which were used to place 
the related coagulation factor V/VIII type C domain of galactose oxidase (PDB entry 1k3i) as 
an aid for model building. The model was built with O (Jones et al., 1991) and refined with 
CNS (Brunger et al., 1998). Crystallographic statistics are summarised in Table 1. The 
figures were made with PyMOL (www.pymol.org). The coordinates of the DDR1-3E3 Fab 
structure have been deposited in the Protein Data Bank (entry code 4ag4). 
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FIGURE LEGENDS 
 
Figure 1. The anti-DDR1 mAbs block collagen-induced DDR1 phosphorylation. DDR1b 
was transiently expressed in HEK293 cells and the cells were stimulated with 10 μg/ml 
collagen I in the absence or presence of 10 μg/ml of the indicated anti-DDR1 mAbs. Aliquots 
of cell lysates were analysed by SDS-PAGE and Western blotting. The blots were probed 
with anti-phosphotyrosine (anti-PY) mAb 4G10 (upper blot) and re-probed with anti-DDR1 
Ab (lower blot). Control, mouse IgG1 isotype control Ab. The experiment was performed 
three times with similar results. See also Figure S1. 
 
Figure 2. The anti-DDR1 mAbs bind to the DS-like domain and do not inhibit ligand 
binding. (A) ELISA showing binding of the indicated anti-DDR1 mAbs to recombinant 
DDR proteins immobilised on 96-well plates. Shown is a representative of three independent 
experiments, each carried out in duplicates. (B) Solid-phase binding assay with recombinant 
DDR1-Fc protein added to 96-well plates coated with either casein or collagen peptide III-23 
(Xu et al., 2011). DDR1-Fc was preincubated with the indicated anti-DDR1 mAbs before 
addition to the wells. Bound DDR1-Fc was detected with anti-human Fc Ab and measured as 
absorbance at 492 nm. Shown is a representative of three independent experiments, each 
carried out in triplicates. 
 
Figure 3. Crystal structure of the DDR1-3E3 Fab complex. (A) Overall structure. The 3E3 
Fab fragment is shown as a surface (tan, light chain; grey, heavy chain) and DDR1 is shown 
as a cartoon (cyan, DS domain; green, DS-like domain; red, collagen-binding loops (Carafoli 
et al., 2009); orange, disulphide bridges). A calcium ion is shown as a magenta sphere and 
the two N-linked glycans are shown as light blue sticks. The N- and C-termini of the DDR1 
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construct are indicated. The β-strands of the jelly roll in the DS and DS-like domains are 
numbered 1-8 and the extra β-strands in the DS-like domain are labelled a-e. (B) 
Superposition of the DS domain (cyan) and the DS-like domain (green) of DDR1. (C) 
Detailed structure of the interface between the DS domain (cyan) and the DS-like domain 
(green) in DDR1. Selected residues are shown in atomic detail and labelled. Hydrogen bonds 
are indicated by dashed lines. See also Figures S2 and S3. 
 
Figure 4. A conserved patch in the DS domain is required for DDR1 signalling. (A) The 
lattice contact resulting in a symmetric DDR1 dimer (see text). The DDR1 molecule on the 
left is in cyan (DS domain) and green (DS-like domain); the DDR1 molecule on the right is 
in grey with the collagen-binding loops (Carafoli et al., 2009) in red. The 2-fold symmetry 
axis is vertical. Selected residues are shown in atomic detail (pink, conserved surface patch in 
the DS domain). (B) Cell surface expression of mutants. Wild-type DDR1b or the indicated 
mutants were transiently expressed in HEK293 cells. The cells were stained on ice with 
10 μg/ml of anti-DDR1 mAb 7A9 (filled grey histograms) or mouse IgG1 isotype control Ab 
(black lines) followed by FITC-conjugated goat-anti mouse IgG and analysis by flow 
cytometry. The experiment was performed twice with similar results. (C) Collagen-induced 
activation of mutants. Wild-type DDR1b or the indicated mutants were transiently expressed 
in HEK293 cells. The cells were stimulated with collagen I at the indicated concentrations (in 
μg/ml). Aliquots of cell lysates were analysed by SDS-PAGE and Western blotting. The blots 
were probed with anti-phosphotyrosine (anti-PY) mAb 4G10 (upper blot) and re-probed with 
anti-DDR1 Abs (lower blot). The experiment was performed three times with similar results. 
(D) Solid-phase binding assay with recombinant DDR1-Fc protein (filled circles, wild type; 
open circles, R32E mutant) added to 96-well plates coated with collagen peptide III-23 (Xu et 
al., 2011). Bound DDR1-Fc was detected with anti-human Fc Ab and measured as 
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absorbance at 492 nm. Shown is a representative of two independent experiments, each 
carried out in duplicates. 
 
Figure 5. Detailed structure of the DDR1-3E3 Fab interface. The 3E3 Fab fragment is 
shown as a semitransparent surface (tan, light chain; grey, heavy chain) and the DDR1 region 
interacting with the Fab is shown as a green cartoon. Selected interface residues are shown in 
atomic detail and labelled. Hydrogen bonds are indicated by dashed lines. 
 
Figure 6. Epitope mapping of anti-DDR1 mAbs. (A) Wild-type DDR1b or the indicated 
mutants were transiently expressed in HEK293 cells. The cells were stained on ice with 10 
μg/ml of the indicated anti-DDR1 mAbs or mouse IgG1 isotype control Ab followed by 
FITC-conjugated goat-anti mouse IgG and analysis by flow cytometry. Binding of isotype 
control Ab is shown by the filled grey histograms. Shown are representative data of at least 
three experiments for each DDR1 mutant. For mean fluorescence values, see Figure S4. (B) 
Surface representation of DDR1 structure showing the location of mAb epitopes determined 
by mutation (mut1, blue: 3G10, 3H10, 7A9; mut6, purple: 1F7, 1F10). The 3E3 footprint 
from the crystal structure is shown in light orange, and mut5 is shown in dark orange. The DS 
and DS-like domains are in cyan and green, respectively. The collagen binding site and 
conserved surface patch (Arg32, Leu99, Leu152, Tyr183) are shown in red and light pink, 
respectively. The C-terminus is indicated.. 
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Table 1. Crystallographic Statistics of the DDR1-3E3 Fab Structure 
 
Data collection  
Space group C2221 
Unit cell dimensions  
     a, b, c (Å) 102.51, 251.48, 75.37 
     α, β, γ (°) 90, 90, 90 
Asymmetric unit content 1:1 DDR1-3E3 Fab complex 
Solvent content (%) 57 
Resolution (Å) 50-2.8 (2.95-2.80)a 
Rmerge 0.079 (0.429) 
<I/σ(I)> 14.3 (3.8) 
Completeness (%) 98.7 (98.9) 
Multiplicity 6.0 (6.1) 
Refinement  
Resolution (Å) 20-2.8 
Reflections 24035 
Protein atoms 2700 (DDR1) + 3169 (3E3 Fab) 
Solvent atoms 2 Ca2+ + 14 H2O 
Rwork/Rfree 0.216/0.286 
R.m.s. deviation bonds (Å) 0.007 
R.m.s. deviation angles (°) 1.4 
Average B-factor (Å2) 53.6 
Ramachandran plot (%)b 91.3/98.1 
aValues in parantheses are for the highest resolution shell. 
bPercentage of residues in favoured and allowed regions (Chen et al., 2010). 
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SUPPLEMENTAL FIGURE LEGENDS 
 
Figure S1. Selected Fab fragments block collagen-induced DDR1 phosphorylation. DDR1b 
was transiently expressed in HEK293 cells. The cells were stimulated for 90 min at 37° C 
with 10 μg/ml collagen I in the presence or absence of the indicated anti-DDR1 mAbs or Fab 
fragments (at 10 μg/ml). Aliquots of cell lysates were analysed by SDS-PAGE and Western 
blotting. The blots were probed with anti-phosphotyrosine (anti-PY) mAb 4G10 (upper blot) 
and re-probed with anti-DDR1 Abs (lower blot). The experiment was performed three times 
with very similar results. 
 
Figure S2. Superposition of DDR1 (cyan, DS domain; green DS-like domain) and the DS 
domain pair of neuropilin-1 (Nrp1, magenta) (Vander Kooi et al., 2007). The DDR1 DS 
domain was fitted to the first DS domain (b1) of Nrp1. The DDR1 DS-like domain and the 
second DS domain (b2) of Nrp1 are related by a ~60° rotation about a vertical axis. 
 
Figure S3. Alignment of selected DDR1 and DDR2 sequences (Homo sapiens DDR1, 
Q08345; Mus musculus DDR1, Q03146; Danio rerio DDR1, XP_001345829; Xenopus 
tropicalis DDR1, XP_002939505; Homo sapiens DDR2, Q16832; Mus musculus DDR2, 
Q62371; Danio rerio DDR2, XP_684261; Xenopus tropicalis DDR2, XP_002933824). The 
numbers above the alignment refer to the human DDR1 sequence. Conserved residues are in 
bold and cysteines are in orange. Predicted N-linked glycosylation sites are underlined. The 
secondary structure elements of the DDR1 structure are indicated above the alignment. Red 
inverted triangles indicate key collagen-binding residues in DDR2 (Carafoli et al., 2009). 
Magenta filled circles indicate calcium ligands in DDR1. Pink diamonds indicate residues 
contributing to the conserved surface patch in the DS domain. Orange inverted triangles 
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indicate residues involved in 3E3 Fab binding (>10 Å2 reduction in solvent accessibility upon 
Fab binding). The seven linear and non-conservative human-to-mouse substitutions in the 
DS-like domain are boxed in blue and labelled mut1-7. 
 
Figure S4. Mean fluorescence values of the flow cytometry data shown in Figure 6. DDR1b 
wild-type or the indicated DDR1 mutants were transiently expressed in HEK293 cells. The 
cells were stained on ice with 10 μg/ml of the indicated anti-DDR1 mAbs or mouse IgG1 
isotype control Ab followed by FITC-conjugated goat-anti mouse IgG and analysis by flow 
cytometry. 




